Jesse Hirner is a Dermatology physician. OpenAlex indexes 25 publications with 262 citations (h-index 7).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1020 Hitt Street
Columbia, MO 652120001
Telephone
573-884-4800Provider last certified this registry record 6 Jul 2022.
Industry payments
3 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- ABBVIE INC.Program year20251 payment
- Janssen Biotech, Inc.Program year20241 payment
- ABBVIE INC.Program year20232 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Sensory organs
42.6%Corticosteroid42.6%Betamethasone Diprop Augmented52%Clobetasol Propionate32%Betamethasone Dipropionate16%Part D<11 patientsDermatology
27.8%Corticosteroid19.8%Triamcinolone Acetonide100%Part D≥28 patientsInterleukin-4 Receptor alpha Antagonist8%Dupixent Pen100%Part D<11 patientsAnti-infectives
12.3%Azole Antifungal12.3%Ketoconazole100%Part D≥11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Immune checkpoint inhibitor‐induced eosinophilic fasciitis: A pharmacovigilance and <scp>EADV</scp> Task force study
Journal of the European Academy of Dermatology and Venereology
2026 - Dupilumab for immune checkpoint inhibitors‐induced pruritic dermatoses: A retrospective, multicentric study
Journal of the European Academy of Dermatology and Venereology
2025 - Post-market surveillance data demonstrate high mortality associated with enfortumab vedotin skin toxicity, not worsened by immune checkpoint inhibitors or corticosteroids
Journal of the American Academy of Dermatology
2025 - Clinical practice guidelines for the management of basal cell carcinoma in Gorlin syndrome
Journal of the American Academy of Dermatology
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Hywel C Williams
University of Nottingham
Mohsen Afarideh, MD, MPH
Mayo Clinic
Brigitte Dréno
Centre National de la Recherche Scientifique
Giovanni Damiani
University of Milan
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”